Isoxazole Compounds Selective α4β2 Nicotinic Receptor Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions related to α4β2 nicotinic acetylcholine receptor (NR) activity face challenges such as non-selectivity, leading to adverse effects, and chronic receptor activation can result in desensitization, limiting the therapeutic benefits of nicotinic agonists.
Innovation Solution
Development of isoxazole compounds that act as positive allosteric modulators (PAMs) to selectively enhance α4β2 NR activity, potentially preventing receptor desensitization and improving the tolerability of nicotinic agonists by reinforcing endogenous cholinergic neurotransmission.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective nicotinic agonists are used to activate NNRs, then beneficial effects such as improved attention and cognitive performance are achieved, but adverse effects including seizures, irregular heartbeat, hypertension, and gastrointestinal effects occur
Solution Approach 1:
The patent applies local quality by developing selective agonists that target specific NNR subtypes (such as α4β2) rather than activating all nicotinic receptors non-selectively. This selective activation at specific receptor locations maintains beneficial cognitive and attentional effects while avoiding the harmful side effects associated with non-selective activation of other receptor subtypes.
Solution Approach 2:
The patent segments the nicotinic receptor system into distinct subtypes (α4β2, α7, etc.) and develops selective agonists for each. By dividing the non-selective activation approach into targeted subtype-specific activation, the patent achieves beneficial effects at specific subtypes while minimizing harmful effects at others.
2Duration of action of stationary object
If chronic treatment with nicotinic agonists is administered, then sustained receptor activation is achieved, but receptor desensitization occurs limiting therapeutic benefits
Solution Approach 1:
The patent employs periodic action by developing agonists with optimized binding kinetics that provide sustained yet controlled receptor activation. The compounds are designed to activate receptors in a controlled temporal pattern that maintains therapeutic effects while preventing chronic desensitization, allowing for sustained action without loss of efficacy.
3Reliability
If selective agonists for α4β2 NNRs are developed, then beneficial cognitive and attentive function improvement is achieved, but dose-limiting emetic liability may be attributed to activation of α3 containing NNRs
Solution Approach 1:
The patent applies local quality by designing agonists with high selectivity for α4β2 NNRs over α3-containing NNRs. This localized selective activation at the α4β2 subtype maintains cognitive benefits while avoiding the emetic liability associated with α3 receptor activation, achieving beneficial effects without the harmful gastrointestinal side effects.
Data Source
AI summary
The invention relates to isoxazole derivatives, compositions comprising such compounds, and methods of preventing or treating conditions and disorders using such compounds and compositions.